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2013 meeting
WHO Malaria Policy Advisory Committee and Secretariat*
Abstract
The Malaria Policy Advisory Committee to the World Health Organization held its fourth meeting in Geneva,
Switzerland from 11 to 13 September, 2013. This article provides a summary of the discussions, conclusions and
recommendations from that meeting.
Meeting sessions included: recommendations for achieving universal coverage of long-lasting insecticide-treated
nets; guidance on estimating the longevity of insecticide-treated nets; improving capacity in entomology and
vector control; a review of the latest evidence on intermittent preventive treatment in pregnancy; improving
dissemination of Malaria Policy Advisory Committee guidance; updates on the development of the global technical
strategy for malaria control and elimination (2016–2025) and the global strategy for control and elimination of
Plasmodium vivax; updates from the drug resistance and containment technical expert group, the evidence review
group on malaria burden estimation, a consultation on malaria case management indicators, and the constitution
of the surveillance, monitoring and evaluation technical expert group; subnational elimination criteria; and consideration
for future evidence review groups, including diagnosis in low transmission settings and testing for Glucose-6-Phosphate
Dehydrogenase Deficiency.
Policy statements, position statements and guidelines that arise from the Malaria Policy Advisory Committee meeting
conclusions and recommendations will be formally issued and disseminated to World Health Organization Member
States by the World Health Organization Global Malaria Programme.
Keywords: WHO, Malaria, Policy making, Mosquito control, Pregnancy, Prevention, Sulphadoxine-pyrimethamine,
Treatment efficacy, Drug resistance, Surveillance, Elimination, Plasmodium falciparum, Plasmodium vivax
Background
The Malaria Policy Advisory Committee (MPAC) to the
WHO held its fourth meeting from 11 to 13 September
2013 in Geneva, Switzerland, following its meetings in
February and September 2012, and March 2013 [1-3].
This article provides a summary of the discussions, con-
clusions and recommendations from that meetinga as
part of the Malaria Journal thematic series “WHO glo-
bal malaria recommendations” [4].
The following sections of this article provide details
and references for the background documents pre-
sented at the open meeting sessions of the committee
on: recommendations for achieving universal coverage of
long-lasting insecticide-treated nets; guidance on estimat-
ing the longevity of insecticide-treated nets; improving
capacity in entomology and vector control; a review of
the latest evidence on intermittent preventive treatment
in pregnancy; updates on the development of the global
technical strategy for malaria control and elimination
(2016–2025) and the global strategy for the control and
elimination of Plasmodium vivax; updates from the drug
resistance and containment technical expert group, the
evidence review group on malaria burden estimation, a
consultation on malaria case management indicators, and
the constitution of the surveillance, monitoring and evalu-
ation technical expert group; subnational elimination cri-
teria; and consideration for future evidence review groups,* Correspondence: mpacgmp@who.int
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including diagnosis in low transmission settings and
G6PD testing.
The MPAC discussion and recommendations related
to these topics, which took place partially in closed ses-
sion, are also included. MPAC decisions are reached by
consensus [5]. The next meeting of the MPAC will be 12
to 14 March, 2014 [6].
Report from the WHO global malaria programme
The Director of the WHO Global Malaria Programme
(WHO-GMP) updated MPAC members on the publica-
tions and major activities of each of the WHO-GMP
units: vector control; diagnosis, treatment and vaccines;
drug resistance and control; and strategy, economics and
evaluation [7]. Topics that were later agenda items dur-
ing the MPAC meeting were not expanded upon during
the presentation; the following summary contains high-
lights of the latest news from WHO-GMP.
Recent vector control documents published by WHO-
GMP for use by national malaria control programmes
(NMCPs) and partners include: (a) test procedures for
insecticide resistance monitoring [8], which are critical
for implementation of actions called for in the Global
Plan for Insecticide Resistance Management (GPIRM)
[9]; (b) an operational manual on indoor residual spray-
ing (IRS) [10]; (c) an operational manual on larval source
management [11] as a supplementary measure for mal-
aria vector control in those areas where it is appropriate;
and, (d) a handbook for malaria control in humanitarian
emergencies [12].
With regard to diagnostic testing, Round 5 of the WHO
product testing of rapid diagnostic tests (RDT) [13] is pro-
ceeding well; data collection is expected to end in Novem-
ber 2013, with publication of the report in April 2014. In
addition, field studies of positive control wells developed
by the Foundation for Innovative New Diagnostics (FIND)
and Reametrix are currently underway in Uganda and
Laos to evaluate their use, utility and acceptability for the
quality control of RDTs in routine health care settings in
malaria-endemic areas; data collection will be completed
by the end of 2013.
Regarding progress with updating the WHO Guidelines
for the Treatment of Malaria [14], the systematic reviews
for updated guidance are proceeding on schedule and the
Chemotherapy Technical Expert Group (TEG) is meeting
in November 2013 to review results. A near final draft of
the guidelines will be presented to MPAC at its next meet-
ing in March 2014 prior to undergoing internal publica-
tion clearance processes within WHO; publication and
dissemination is expected to take place in mid 2014.
The WHO-GMP Director also updated MPAC on the
latest developments for Seasonal Malaria Chemopreven-
tion (SMC) [15]. SMC was recommended by MPAC at its
inaugural meeting in 2012. Since then, three workshops
have been organized by WHO in collaboration with the
Université Cheikh Anta Diop in Senegal, the London
School of Hygiene and Tropical Medicine, and the Roll
Back Malaria (RBM) West African Regional Network.
These meetings have provided countries with support
and helped guide SMC planning and implementation.
Nine countries out of 14, where the intervention is po-
tentially appropriate using amodiaquine plus sulphadoxine-
pyrimethamine, have adopted and added SMC to their
malaria control strategies. Based on their implementation
plans, 19 million children could potentially benefit from
SMC during the next three malaria seasons, ie., 2013–
2015. Unfortunately, large-scale implementation in these
nine countries has yet to start due to funding constraints,
although small-scale implementation has begun in four of
them - Mali, Senegal, Niger, and Nigeria. A field guide to
SMC implementation was published in French in August
2013 and both it and the previously released English ver-
sion are now available on the WHO-GMP website [16].
With regard to training, WHO conducted five courses
between June and September 2013, primarily in Africa and
the Commonwealth of Independent States (CIS), covering
nearly 100 national malaria programme staff, on topics
ranging from surveillance, monitoring and evaluation to
the prevention of re-introduction of malaria. In August
2013, WHO-GMP published malaria training modules on
case management [17] and entomology and vector control
[18]; they are available for download from the document
centre of the WHO-GMP website.
On drug resistance and containment, WHO, together
with affected countries, developed the Emergency Re-
sponse to Artemisinin Resistance (ERAR) in the Greater
Mekong subregion [19]. This regional framework for ac-
tion from 2013 to 2015 is in line with Global Plan for
Artemisinin Resistance Containment (GPARC) [20] rec-
ommendations. It was launched on World Malaria Day
in April 2013 in Phnom Penh, Cambodia, where WHO
has now opened a new regional hub to coordinate re-
sponse efforts. The aim of ERAR is not to replace exist-
ing national, regional or global strategies, but to increase
the coordination, quality and coverage of interventions
in the Greater Mekong subregion. MPAC welcomed this
coordinated approach, and praised the Global Fund for
its commitment of $100 million to containing artemisi-
nin resistance in the subregion. However, they expressed
concern at the news of continued production of oral
artemisinin-based monotherapy, the use of which in-
creases the risk of the spread of artemisinin resistance.
They urged the National Drug Regulatory Authorities of
the 13 countries (Angola, Bolivia, Cape Verde, Colombia,
Equatorial Guinea, Gambia, Myanmar, Papua New Guinea,
Sao Tome and Principe, Somalia, Swaziland, Timor
Leste, and Vanuatu) that still allow the marketing of
oral artemisinin-based monotherapy medicines to ban
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their sale in order to help lower demand for continued
production.
A core role of WHO-GMP is to keep an independent
score of global progress in malaria control and elimination
[21]. One of the ways it does this is via the annual World
Malaria Report (WMR) [22], which will be launched this
year on 11 December in Washington, D.C. WHO-GMP is
also finalizing an updated Malaria Programme Review
manual after extensive input from partners, which will be
a much simpler version of the edition released in 2010
[23]. This development was strongly welcomed by MPAC,
who noted that NMCPs need a simple and useful way of
measuring and reviewing their control and elimination
programme performance. They also welcomed progress
with the Malaria Situation Room [24], which was formally
launched at the Special Summit of the African Union on
HIV/AIDS, Tuberculosis and Malaria in Abuja, Nigeria
in July 2013; it is a joint initiative of WHO, RBM,
the African Leaders Malaria Alliance, the Office of the
UN Secretary-General’s Special Envoy for Financing the
Health Millennium Development Goals and for Malaria,
as well as the International Federation of Red Cross and
Red Crescent Societies. The Malaria Situation Room iden-
tifies bottlenecks to achieving universal access to malaria
control and finds solutions in the ten countries with the
highest malaria burden in Africa: Nigeria, the Democratic
Republic of the Congo, the United Republic of Tanzania,
Uganda, Mozambique, Côte d’Ivoire, Ghana, Burkina Faso,
Cameroon and Niger. Together these countries account
for more than 70% of Africa’s malaria burden, and 56%
of the global malaria burden. The Global Fund, the US
President’s Malaria Initiative and UNICEF have recently
joined the Situation Room and are contributing to the
weekly calls.
MPAC commended the work of WHO-GMP and their
partners in the global malaria community in supporting
countries in their efforts to monitor and reduce their
malaria burden. The next report from WHO-GMP to
MPAC in March 2014 will focus on the key findings
from the World Malaria Report 2013.
Universal coverage of long-lasting insecticide-treated nets
Following its establishment at the September 2012 MPAC
meeting, and the subsequent open call and selection
process for members in early 2013 [25], the Vector Con-
trol TEG (VC TEG) met for the first time in July 2013 to
begin its task of reviewing and making recommendations
on the use and appropriate mix of vector control inter-
ventions in the control and elimination of malaria [26]. A
major output from that meeting was a report to MPAC
with recommendations on methods for achieving and
sustaining universal coverage of long-lasting insecticidal
nets (LLIN) [27,28].
LLINs have played an important role in the remarkable
success in reducing malaria burden over the past decade
[22]. They are a core prevention tool and are widely used
by people at risk of malaria. However, LLINs wear out
gradually over time and need to be replaced. Therefore,
sustaining universal LLIN coverage remains challenging
for many countries. The VC TEG considered how univer-
sal coverage, defined as universal access to and use of
LLINs, can be achieved and sustained operationally.
Among the conclusions of the VC TEG was that in
order to maintain universal coverage, countries should
apply a combination of mass distribution and continuous
distribution through multiple channels, in particular ante-
natal and immunization services. The term “continuous”
was defined as distribution systems that deliver nets con-
tinuously and without interruption over time, as opposed
to “campaigns” which deliver a consignment of nets to a
defined target population in a single time-limited oper-
ation. The VC TEG recommended that mass campaigns
should be repeated, normally at an interval of no more
than three years, unless there is reliable evidence that a
different interval would be appropriate. They also recom-
mended that continuous distribution channels should be
functional before, during and after the mass distribution
campaigns to avoid any gap in universal access to LLINs.
The VC TEG recommended that there should be a sin-
gle national plan, under the leadership of the NMCP,
for both continuous and campaign distribution strategies.
This unified plan should include a comprehensive quanti-
fication and gap analysis for all public sector LLIN distri-
bution channels. In addition, each NMCP should develop
its own LLIN distribution strategy, based on an analysis
of local opportunities and constraints. The strategy
should identify a combination of cost-effective and equit-
able distribution channels to achieve and sustain universal
coverage, which in addition to mass campaigns and con-
tinuous distribution through antenatal clinics (ANC)
and the Expanded Programme on Immunization (EPI),
could include channels such as schools, community-
based platforms, religious networks, agricultural and
food-security support schemes, and the private and
commercial sector. Ministries of Health should ensure
that NMCPs have adequate human and financial re-
sources for efficient programme management, as well as
for LLIN procurement and distribution.
The VC TEG also recommended that because the life-
span of LLINs vary widely among different nets and set-
tings, making it difficult to plan the frequency at which
replacement nets need to be procured and delivered, all
LLIN programmes should carry out durability monitor-
ing using WHO guidance [29]. In addition, there should
be efforts to improve LLINs through repair of small
holes before they become bigger, as well as behaviour
change interventions to improve net longevity and use.
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It is important to note that the VC TEG did not recom-
mend periodic “top-up campaigns”. However, the VC TEG
suggested that a NMCP could consider top-up strategies
(rather than full replacement without taking current net
ownership into account) if 40% or more of the target
population have LLINs that are less than two years old.
MPAC fully endorsed the VC TEG’s recommendations
for sustaining universal coverage of LLINs, as well as the
indicators suggested for monitoring progress towards uni-
versal coverage (e g, repeated longitudinal estimates of the
percentage of the population with access to a LLIN within
the household). The report was approved pending edits to
improve the clarity and conciseness of the document prior
to WHO publication. These edits were adopted and the
WHO recommendations for achieving and sustaining uni-
versal coverage of LLINs are now available on the WHO-
GMP website [30].
Estimating the longevity of insecticide-treated nets
The VC TEG presented MPAC with a report and draft
guidance note on estimating the longevity of LLINs for
malaria control [31,32]. The durability of LLINs in the
field has become a critical issue for the success of mal-
aria control in areas where LLINs are being applied for
malaria prevention for two main reasons: (a) it has been
shown by various modelling exercises that increasing
LLIN durability by one or two years on average would
have a huge impact on the cost of malaria prevention, in
the order of $500-700 million savings over five years;
and, (b) there are increasing data suggesting that there is
a wide variation of LLIN durability between different lo-
cations or populations. This implies a need to acquire
country- or region-specific data on LLIN performance
so that LLIN procurement decisions can be based on price
per year of protection rather than unit price per net.
The VC TEG noted that significant progress has been
made towards performance-based procurement with the
release in 2011 of the “Guidelines for monitoring the
durability of LLINs under operational conditions” by
WHO [29], which not only addresses some of the meth-
odological issues but also encourages countries to in-
corporate assessment of LLIN performance as part of
their distribution efforts. Furthermore, the concept note
on a system to improve LLIN procurement through
market competition [33] issued by WHO in 2011 clearly
states the importance of “value for money” and that “for
LLINs, the criteria for comparison could be ‘cost per
median year of net life under local conditions of use’”.
However, the current guidelines are not comprehensive
enough to allow countries that have already started to
collect data on LLIN performance to translate their find-
ings into the required “median LLIN survival”, and an
expansion of these guidelines was, therefore, needed.
LLIN durability and survival depend on two factors:
(a) net attrition, ie., complete loss of nets; and, (b) phys-
ical integrity, ie., holes and tears in nets still existing in
households. Net attrition from households includes both
LLINs that are potentially still in use elsewhere (given
away for others to use, stolen) and nets that are no lon-
ger usable or available (discarded, destroyed, used for
other purposes). The expanded guidance from the VC
TEG provides country programmes and partners with a
method for calculating the functional survival of LLINs
from field data obtained from prospective or retrospect-
ive surveys, as well as a method to estimate the median
survival time of LLINs. These methods are based on the
best available evidence to date.
MPAC fully endorsed the VC TEG’s recommendations
for estimating the longevity of LLINs, concluding that it
will help provide guidance to countries to track LLIN dur-
ability in the field in order to support management of re-
supply and to inform global level procurement decisions
in conjunction with urgently needed new, more predictive
textile laboratory testing currently under consideration by
WHO. Following edits to improve the clarity and concise-
ness of the guidance note, the WHO guidance on estimat-
ing the longevity of LLINs was finalized and is now
available on the WHO-GMP website [34].
Improving capacity in entomology and vector control
The VC TEG presented recommendations for countries
and partners to improve capacity in entomology and vec-
tor control [35,36]. The VC TEG explained that malaria
control is at a critical juncture and that the goal of malaria
elimination in many settings might not be achieved with-
out adapting to the changing threats and opportunities
for controlling transmission. Progress in global malaria
control over the past decade has been largely gained
through investments in vector control, especially insecticide-
treated mosquito nets (ITNs) and IRS. In order to sustain
and build further on these gains, there is a need to im-
prove the efficiency of malaria vector control, including
better targeting of interventions, and more effective man-
agement of anopheline resistance to insecticides. These
challenges can only be met by national staff with the train-
ing, support and career structures that allow them to
effectively plan, monitor, evaluate, and manage vector con-
trol efforts.
The VC TEG recommended that Ministries of Health
should ensure that each NMCP has the human capacity
and infrastructure to support vector control and entomo-
logical monitoring, including monitoring for insecticide
resistance. The NMCP should establish or strengthen an
intersectoral coordination mechanism to develop a long-
range strategic plan for building human resources and sys-
tems for public health entomology and vector control. The
plan should include: conducting training needs assessments
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and curricula review for pre-service and in-service training
(including epidemiology and management). This will en-
sure training is directly relevant to the expected skills of
staff tasked with entomological monitoring and vector con-
trol. The plan should also review, revise or establish posts
and career development structures for entomology and vec-
tor control specialists at national and subnational levels
within Ministries of Health or other appropriate go-
vernment structures. In cases where basic entomological
capacity is lacking within the NMCP, the intersectoral co-
ordination mechanism should include the establishment of
agreements with national universities and training and re-
search institutions to provide ongoing training and tech-
nical support, including reference laboratory services for
entomological monitoring and vector control.
These sentiments on the urgent need for human cap-
acity strengthening in the field were strongly supported
by MPAC. They endorsed the VC TEG recommenda-
tions, and these are now available on the WHO-GMP
website as a WHO guidance note for countries and part-
ners to improve capacity for malaria entomology and
vector control [37].
Intermittent preventive treatment in pregnancy
In October 2012, WHO updated the malaria in pregnancy
(MIP) policy for intermittent preventive treatment during
pregnancy with sulphadoxine-pyrimethamine (IPTp-SP).
WHO recommends that women who live in moderate to
high malaria transmission areas should receive IPTp-SP as
early as possible in the second trimester and at each
scheduled ANC visit thereafter, provided that each SP
dose is given at least one month apart [38].
Since the updated IPTp policy was released, multiple
countries throughout sub-Saharan Africa have reviewed
the new policy and plan to update their country policies
and start programme implementation. As a further step
in the policy making process, the Evidence Review
Group (ERG) on IPTp met from 9 to 11 July, 2013 to as-
sess the results of recently completed multicentre clin-
ical trials on mefloquine use for IPTp (IPTp-MQ), and
to review the evidence on the effectiveness of IPTp-SP
in relation to Plasmodium falciparum antifolate resist-
ance and decreasing malaria transmission [39]. In rela-
tion to mefloquine, the specific objectives of the ERG
meeting were to review evidence of the efficacy, safety
and tolerability of 15 mg/kg MQ for IPTp, given as sin-
gle or split dose, compared to SP in HIV-negative preg-
nant women, and the benefit of three monthly doses of
IPTp-MQ added to daily co-trimoxazole (CTX) prophy-
laxis in HIV-infected pregnant women.
The MPAC reviewed the ERG recommendations [39],
and agreed that MQ at the 15 mg/kg dose regimen
should not be recommended for IPTp given its adverse
events and poor tolerability. In relation to SP resistance,
MPAC recognized that in many areas where parasites
with quintuple mutations conferring antifolate resistance
have been identified, IPTp with SP still confers benefit
in terms of pregnancy outcomes. In a small number of
discrete, limited areas in eastern and southern Africa,
resistance of P. falciparum to SP has reached a level
at which IPTp-SP may no longer be effective in prevent-
ing low birth weight. These are areas where there are
P. falciparum parasites carrying six resistance mutations
in dhfr and dhps genes, including the A581G dhps
mutation. On balance, MPAC concluded that there is
currently insufficient data to determine at what level
of resistance IPTp-SP should be discontinued in the
absence of an established and effective alternative. Simi-
larly, MPAC concluded that there are currently in-
sufficient data to define the level of P. falciparum
transmission at which IPTp-SP may cease to be cost-
effective from a public health point of view. Further-
more, natural fluctuations in malaria incidence from
year to year, and the low cost of the intervention as de-
livered through the Maternal and Child Health system,
call for significant caution before discontinuing IPTp-SP.
More data are needed and will be reviewed when avail-
able. Until that time, MPAC strongly recommended
that countries should continue to implement the current
WHO policy that women who live in moderate to high
malaria transmission areas should receive IPTp-SP as early
as possible in the second trimester, and at each scheduled
ANC visit thereafter, provided that each SP dose is given
at least one month apart [38]. WHO-GMP has developed
a policy brief to provide guidance to national health
authorities in Africa to support the implementation of
IPTp-SP; it is available on the WHO-GMP website [40].
Global technical strategy for malaria control and
elimination (2016–2015)
In response to a request by MPAC in 2012, and an ex-
pression of support by WHO Member States at the 2013
World Health Assembly in May, WHO-GMP is coordin-
ating the development of a Global Technical Strategy for
Malaria Control and Elimination (GTS) for 2016–2025.
As requested, the GTS will articulate the goal and global
targets for malaria control and elimination over the next
decade. This will be a unifying document that syn-
thesizes current policy recommendations and compre-
hensive, evidence-based and cost-effective strategies for
WHO Member States to use in developing their own
strategies. The document will also provide a platform for
ensuring that the impressive gains of the last decade are
sustained, and that further progress is accelerated along
the pathway to elimination.
The Chair of the recently formed GTS Steering Commit-
tee provided an update to MPAC on progress since its last
meeting in March 2013 [41]. The Steering Committee,
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composed of 14 leading malaria technical experts, scien-
tists and representatives of endemic countries, who have
been tasked with guiding WHO-GMP on the development
of the GTS, leading evidence reviews and ensuring that the
process is rigorous and inclusive of national and regional
inputs, met for the first time from 29 to 30 July, 2013 in
Geneva [42]. The Steering Committee discussed its work
plan and the GTS development timeline so that its findings
will be ready to be presented to WHO Member States for
consideration at the 2015 World Health Assembly.
The GTS will be developed through an inclusive process
that draws on existing country and regional strategies as
well as consultations with WHO Regions, international
experts and country programmes. The key contribution to
the GTS development process will be the convening of
seven regional expert consultations led by the WHO
Regional Offices from February to May 2014. Concurrent
with the GTS development process, RBM will develop the
Global Malaria Action Plan 2 (GMAP 2), the second gen-
eration of an RBM consensus document which provides
the global framework for coordinated action by all malaria
stakeholders supporting acceleration of malaria control
and elimination efforts. The GTS will serve as the tech-
nical foundation for the GMAP 2 and the two documents
will be developed in a synchronous, collaborative process
with shared goals and global targets for malaria over the
next decade. At the request of MPAC, a mechanism has
been put in place to ensure that the GTS Steering Com-
mittee and the RBM GMAP 2 Taskforce work together to
ensure full complementarity of both documents. Four
members of the GTS Steering Committee and the GMAP
2 Taskforce will sit on both boards and the Executive
Director of the RBM Partnership Secretariat and the
Director of WHO-GMP will be ex officio members of both
groups. It is envisioned that the GTS and GMAP 2 will be
launched as companion documents in late 2015, after con-
sideration by the World Health Assembly for the GTS and
RBM Board adoption of the GMAP 2.
MPAC commended the GTS Steering Committee and
WHO-GMP on progress to date, and the leadership of
WHO-GMP and RBM on the close alignment of the
processes for the GTS and GMAP 2. MPAC members
were especially supportive of the inclusive process that
will involve country and regional input; these will be
central to the development of the GTS and critical for
its success. To inform the goal and targets of the GTS, a
baseline analysis to look at all existing regional and na-
tional malaria strategies is currently underway. The GTS
Steering Committee will next update MPAC at its March
2014 meeting in Geneva.
Global strategic plan for Plasmodium vivax malaria
WHO-GMP provided MPAC with an update on progress
with the Global Strategic Plan for Plasmodium vivax
malaria [43,44]. The first writing committee meeting
took place in Barcelona on May 31, 2013. An outline
was drafted for each of the Thematic Review topics with
a focus on programmatic relevance, in particular, biology,
epidemiology, vector control, diagnosis and treatment, sur-
veillance and elimination, costs and cost-effectiveness, and
research priorities. In addition, ten countries (Azerbaijan,
Brazil, Cambodia, China, Ethiopia, India, Indonesia, Iran,
Nicaragua and Papua New Guinea) with diverse P. vivax
endemicity have been selected for Country Landscape
Briefs. These briefs will include details of their P. vivax epi-
demiology, interpretation of distributional patterns and
trends over time, malaria control interventions (policy and
practice) as well as gaps and constraints in relation to
WHO policy guidance. Work is in progress and a draft of
the Global Strategic Plan is expected in early 2014.
The schedule for developing the P. vivax plan has been
modified so that it is more closely aligned with the time-
line for the GTS, and will, therefore, be better and more
fully integrated with it in terms of content. The planned
P. vivax regional consultations will now take place
alongside the GTS regional consultations during the first
half of 2014. An update will be provided to MPAC at its
next meeting in March 2014.
Improving dissemination of MPAC guidance
WHO-GMP updated MPAC on work it has undertaken to
improve knowledge management across the three levels of
the organization (headquarters, regional offices and coun-
try offices), in particular to improve the dissemination of
policy recommendations and MPAC meeting reports, to
strengthen its external and internal communications in-
frastructure, as well as possible suggestions for MPAC-
related information management [45,46].
Over the past year, WHO-GMP has worked on strength-
ening its knowledge management infrastructure while at
the same time improving its presence at high-level govern-
mental events and scientific conferences to generate better
visibility for its policy recommendations. The biggest
change to date is the upgrading of the external communi-
cations architecture, which has the central WHO malaria
website [47] at its core.
The malaria website has been updated and re-built in
six official WHO languages, with the new content archi-
tecture allowing easier access to information on all inter-
vention areas, and providing a clear prioritization of
content. New site features include a news archive to
track all announcements, a media centre for journalists
and the advocacy community, and a document centre
containing all malaria documents in one place, with im-
proved navigation and search functionality.
The French content has been significantly expanded,
bringing about a major improvement in the way material
is presented to NMCPs and partners in Francophone
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countries. In addition, many documents containing out-
dated guidance have been archived and taken off third-
party sites. The long-term vision is to build a global
information hub on malaria that pulls together all of
WHO’s malaria information, including information from
other programmes and regional sites.
WHO-GMP also provided an update about other dissem-
ination channels, such as document launches at high-level
inter-governmental events, information about audience
profiles and website statistics, and opportunities for further
strengthening of dissemination efforts.
MPAC members enthusiastically welcomed ongoing
efforts to improve knowledge management, in particular
the changes to the WHO-GMP website. They also wel-
comed WHO-GMP considering the presentation of con-
tent from a multilingual perspective and requested that
WHO-GMP consider adding a section that brings to-
gether Portuguese-language publications in one place.
Drug resistance and containment
The Drug Resistance and Containment (DRC) TEG up-
dated MPAC on its 27 to 28 June, 2013 meeting in Geneva
[48]. Among the agenda items discussed at that meeting
was the Emergency Response to Artemisinin Resistance
(ERAR) in the Greater Mekong subregion [19], which is a
framework that aims to strengthen current efforts and
increase cross-border collaboration between Cambodia,
Myanmar, Thailand, and Viet Nam on containing resist-
ance and eventually eliminating malaria. MPAC endorsed
the DRC TEG’s recommendations on the current ERAR
tier designations. Based on recent study results they rec-
ommended that the following additional provinces should
be designated as Tier I (ie., areas for which there is cred-
ible evidence of artemisinin resistance): Bago East and
Kayin provinces in Myanmar, and Preah Vihear province
in Cambodia. Kayah province in Myanmar is also likely to
meet the Tier I designation, but the recommendation is
pending the availability of quality control data from thera-
peutic efficacy studies. The district of Attapeu in Laos,
currently designated as Tier II, may also be changed to
Tier I after a review of new data.
The DRC TEG also informed MPAC that the Tracking
Resistance to Artemisinin Collaboration (TRAC) study
has confirmed areas in Southeast Asia where slow clear-
ance phenotype P. falciparum have been identified by
high day 3 positivity rates during routine therapeutic ef-
ficacy studies. They have also identified new areas where
increased vigilance is needed. A comparison of the de-
tailed parasite clearance data from the TRAC studies
with that of day 3 positivity rates during therapeutic effi-
cacy studies, supplemented by preliminary modeling re-
sults, indicates that the current TEG-recommended
threshold of ≥10% day 3 positivity rates for defining sus-
pected artemisinin resistance is still appropriate.
MPAC endorsed the DRC TEG recommendation to
identify a replacement for the current first-line treatment,
atovaquone-proguanil, for uncomplicated P. falciparum
malaria in Western Cambodia since it is effectively a
monotherapy and hence vulnerable to resistance, illus-
trated by reports of high failure rates in areas where it has
been deployed. The DRC TEG concluded that the best al-
ternative treatment option is the fixed combination of
pyronaridine-artesunate, but that a study must be conducted
urgently to confirm its efficacy in Western Cambodia. The
extension of artemisinin-based combination therapy (ACT)
regimens dihydroartemisinin-piperaquine or artemether-
lumefantrine from three to either five or seven days could
be an alternative option in areas where ACT is failing, but
this will also require additional efficacy and safety studies.
Other updates provided to MPAC by the DRC TEG in-
cluded: a review of suspected artemisinin resistance in
Suriname and Guyana; recent developments on assessing
parasite clearance; an update on molecular markers for ar-
temisinin resistance; an update on in vitro artemisinin sus-
ceptibility testing; the outcome of recent modelling efforts
on multiple first-line treatments; and developments in the
study design and implementation of mass drug administra-
tion as a tool for eliminating artemisinin-resistant malaria.
Further details about each of these topics are included in
the DRC TEG meeting report which is available on the
MPAC September 2013 meeting background documents
page of the WHO-GMP website [49].
The next meeting of the DRC TEG is scheduled to
take place in early 2014, and an update will be provided
to MPAC at its next meeting in March 2014.
Malaria burden estimation
The ERG on malaria burden estimation (ERG MBE) met
for the last of its three planned meetings from 8 to 9 July,
2013 [50] to: (a) discuss updates on relevant work since
their previous meeting in January 2013; (b) achieve con-
sensus on the methods that should be used by WHO and
in the World Malaria Report (WMR) to estimate malaria
cases and deaths; and, (c) develop research agendas to im-
prove estimates and address bottlenecks that prevent rec-
onciliation of different methodologies and results.
The ERG MBE Chair presented MPAC with its con-
clusions and recommendations for WHO malaria mor-
bidity estimates [51]. These included: (a) for the 2013
WMR, WHO-GMP should use the same methodology
for case estimation as they currently use. However, for
2014 and after, WHO-GMP should use the Malaria Atlas
Project (MAP) “cube” case estimates for African coun-
tries without strong surveillance systems; (b) WHO-
GMP will need to continue to present time series of
cases and deaths in each WMR so that journalists and
other consumers of the information will not create their
own time series by extracting annual estimates from
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different WMRs (which will be influenced by changes in
methodology and data validation); (c) WHO-GMP should
discuss with partners the feasibility of collecting preva-
lence data through household surveys such as the Malaria
Indicator Survey (MIS) on all age groups (not just six to
59 months) so that the age pattern of P. falciparum para-
site rates (PfPR) can be further examined. The sample of
older children and adults available at home at the time of
a survey may not be an accurate representation of the
population as a whole, but the data would still be useful;
(d) the assumptions about parasitaemia and different care-
seeking behaviours would benefit from further validation.
To do so, the analysis examining parasite prevalence
stratified by type of care-seeking behaviour should be sup-
plemented with more recent surveys and surveys from
outside of Africa, if available (such as from the WHO
Eastern Mediterranean Region). If the analysis indicates
highly variable results by region, the assumptions used
may need to be country- or region-specific; and, (e)
WHO-GMP should report on parasite prevalence as one
of their key indicators (in addition to cases and deaths).
As with cases and deaths, the WMR will show country-
reported parasite prevalence values and modelled parasite
prevalence (from MAP). WHO-GMP will need to con-
sider the factors that complicate reported parasitaemia.
Since prevalence changes by season, presenting a static an-
nual value may be misleading. In some areas outside of
Africa, estimates of cases may be of higher quality than
MAP prevalence estimates, so WHO-GMP will need to
decide whether to convert case data into prevalence values
in order to generate estimates of PfPR for the entire globe.
WHO-GMP will then need to determine whether country
consultations on PfPR will be required, as with cases and
deaths.
MPAC endorsed the ERG MBE’s recommendations
and conclusions that generating user-friendly and trans-
parent methodologies for estimates of malaria preva-
lence, cases and deaths might help increase country
participation and ownership over the estimates, which in
turn, should encourage more investment in data quality.
Regarding WHO malaria mortality estimates [51], the
ERG MBE conclusions and recommendations were that:
(a) WHO-GMP should use the same methodology for
the 2013 WMR malaria mortality estimates as has previ-
ously been used. Once further research is conducted,
WHO-GMP may want to change the methodology for
estimating malaria deaths, but there is no evidence to
justify such a change at the present time; (b) WHO-
GMP should also use the same assumptions in the 2013
WMR that have previously been used. In the future,
some assumptions, such as a fixed case fatality rate
(CFR) for estimates outside Africa, should potentially be
revisited. The ERG recommended against applying a
case fatality rate to estimate the number of malaria
deaths for highly endemic countries in Africa; ERG MBE
members felt that it would be difficult to identify an ap-
propriate CFR in the light of changing treatment prac-
tices. Of note, in Africa WHO uses verbal autopsies as a
key source of information on malaria mortality rates in
children under five years of age; (c) WHO-GMP and the
global malaria community should be clear that the age
group “>5 years” should not be interpreted as meaning
“adults” as a significant proportion of morbidity and
mortality in this broad age group can refer to persons
between five and 15 years of age.
MPAC thanked the ERG MBE for its careful and dili-
gent work over the past year, and particularly to all the
researchers with their methodologically diverse back-
grounds who participated and actively contributed to the
discussions on how to improve malaria estimates now
and in the future. MPAC concluded that given that the
malaria mortality research agenda is just in its beginning
stages, additional meetings of a ERG MBE may be neces-
sary in order to evaluate new methodologies in the fu-
ture. In the meantime, the Surveillance, Monitoring and
Evaluation TEG (SME TEG) would take over the func-
tions of the current ERG, and the ERG MBE would be
considered closed. WHO-GMP has already accepted the
ERG MBE’s suggestions for improvement to the 2013
WMR, which will be released in December 2013.
Malaria case management indicators
WHO-GMP presented MPAC with the conclusions from
an informal consultation on malaria case management in-
dicators that took place in Geneva from 10 to 11 July,
2013 [52,53]. The meeting brought together experts and
WHO technical staff to share current knowledge and
practices regarding monitoring malaria case management.
Several recent developments in malaria control policies
and practices, for example the 2010 WHO recommenda-
tion for universal diagnostic testing of all suspected mal-
aria cases and the 2012 launch of the “T3: Test. Treat.
Track” Initiative [54], have highlighted the need for im-
proved monitoring of malaria case management practices
since current approaches have important limitations, par-
ticularly in high-burden countries. For example, national
programme data on diagnostic testing and treatment are
rarely linked in a way that facilitates tracking of testing
and treatment practices. Although national household sur-
veys are increasingly available, the validity of information
on diagnostic testing and treatment collected has been
questioned. Health facility-based surveys can address
some of the limitations of programme and household sur-
vey data on malaria diagnostic testing and treatment, as
patient testing and treatment information can be reliably
linked and recall bias of respondents can be reduced.
The limitations of current case management indica-
tors were acknowledged by MPAC. Ultimately, routine
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monitoring needs to be improved; however, the need for
better information on malaria case management is acute.
As an immediate next step, WHO-GMP will draft a proto-
col and conduct a pilot using Service Availability and
Readiness Assessments (SARA) of health facilities to ex-
plore whether using SARAs to collect information on mal-
aria testing and treatment is feasible. If so, the results will
be made available and the practice will be promoted more
widely. MPAC supported the need to be able to employ
more focused, facility-level surveys in the short term while
improving routine systems for the long term. They sug-
gested that this area of work should be linked to the terms
of reference for the new SME TEG.
Surveillance, monitoring and evaluation
WHO-GMP updated MPAC on progress with constitut-
ing the SME TEG [55]. Since its last meeting and at the
request of MPAC, the draft terms of reference for the
SME TEG were presented to the RBM Monitoring and
Evaluation Reference Group (MERG) in New York in
May for input. These were incorporated and presented
to MPAC for approval [56].
The SME TEG will report to MPAC and provide ad-
vice to WHO on surveillance, monitoring and evaluation
at the national, regional and global level. This includes:
(a) choice of indicators for monitoring the financing,
coverage, quality, and impact of malaria control inter-
ventions at the national and global level; (b) strategies
for obtaining, synthesizing and disseminating infor-
mation on the indicators globally, including modelled
estimates of intervention coverage and disease burden;
(c) guidance that WHO provides on (i) surveillance of
infections, cases and deaths and the use of these data in
decision-making, (ii) establishing systems for monitoring
programme financing and coverage, (iii) evaluating the
impact of malaria interventions and programmes; (d)
evaluating the accuracy and integrity of SME data at the
national, regional and global level; (e) approaches for
strengthening the capacity of WHO Member States to
generate and use key information; and, (f ) identifying
gaps in evidence and suggesting priority research areas
in the field of SME.
WHO-GMP will soon begin a call for CVs of inter-
ested experts for the SME TEG and will constitute the
group in early 2014. It is scheduled to meet for the first
time in the first half of 2014, and an update will be pro-
vided to MPAC at its next meeting in March 2014.
Subnational elimination criteria
Some countries have undertaken malaria elimination at
subnational level. For example, in the Philippines, 27 out
of 80 provinces have been declared malaria-free to date.
However, there are no global guidelines for achieving
and validating malaria-free status in smaller subnational
geographic areas such as states, regions or provinces. At
its last meeting, MPAC concluded that subnational elim-
ination targets, should countries choose to pursue them,
could be important internal milestones for countries, as
well as being potentially important international mile-
stones, especially in larger countries.
WHO-GMP plans to update the current guidelines on
elimination [57], including certification, in 2014. Since
the criteria for subnational certification should be con-
sistent with the criteria for WHO national-level certifi-
cation, WHO-GMP presented only the broad criteria
for subnational malaria elimination to MPAC at this
September 2013 meeting [58,59]; they will finalize and
submit them to MPAC after updating the global guide-
lines in 2014.
WHO-GMP outlined some of its general principles for
subnational elimination: (a) the processes for validation
of malaria-free status should emulate the WHO certifi-
cation scheme; (b) definitions used in WHO elimination
and certification guidelines e.g. “malaria free area” are
valid for subnational elimination; (c) “certification” based
on explicit criteria is preferable to a “declaration”, which
may easily become arbitrary; and, (d) elimination, once
achieved, should free up resources for areas where mal-
aria is still a public health burden, although there are
ongoing resource requirements to prevent reintroduc-
tion of malaria.
In addition, the process of achieving subnational elim-
ination should be standardized and officialized; a na-
tional team should conduct evaluation and a higher-level
experienced commission should be established to evalu-
ate and validate the work of the elimination team. The
team should if possible include external international ex-
perts so as to enhance the validity and credibility of the
process.
The evaluation criteria by which “malaria-free” subna-
tional elimination status would be measured would be:
(a) no locally transmitted case in the last three years, at
the minimum; (b) a malaria surveillance system set up
and implemented with full coverage of the area under
consideration; and, (c) a comprehensive plan of action
with continued political and financial support to prevent
re-establishment of transmission.
The role of WHO in this process would be to provide
technical assistance to its Member States, if requested.
However, WHO does not have, and is not expected to
have, sufficient staff to participate in the certification of
all candidate subnational areas in all countries; these
would be the sole responsibility of the country itself.
MPAC supported the overall concept of subnational
elimination for the many advantages outlined by WHO-
GMP. It also voiced strong support for WHO-GMP’s re-
stricted participation in the process, which it saw as a
country-led endeavour. Members agreed that the criteria
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for undertaking subnational elimination should follow the
guidelines for national elimination; however they cau-
tioned WHO-GMP over the use of the word “certifica-
tion”, preferring to restrict it only for national elimination
and to use an alternative, such as “validation” or some-
thing similar, for subnational malaria-free status confirm-
ation. “Validation” would be a national responsibility that
would follow the WHO guidelines for national elimin-
ation, but might be modified to country-specific require-
ments. MPAC concluded that once the guidelines for
elimination have been updated, more discussion will be
needed on technical issues, such as whether PCR facilities,
or an extensive database, will be essential requirements for
subnational validation and to what extent the rigorous re-
quirements for national certification of elimination will be
adapted for subnational application.
Discussion
The wording for recommendations were finalized by
MPAC during their closed session following the two and
a half days of open sessions; conclusions have been in-
cluded in the summaries of the meeting sessions above,
and links to the full set of meeting documents have been
provided as references.
Position statements and policy recommendations made
by the MPAC are approved by the WHO Director-
General, and will be issued formally and disseminated to
WHO Member States by WHO-GMP or the WHO Re-
gional Offices. Conclusions and recommendations from
MPAC meetings are published in the Malaria Journal as
part of this series.
MPAC provided suggestions for the agenda for its next
meeting to the WHO-GMP Secretariat. In addition to
requesting updates from each of its four TEGs (Chemo-
therapy, Drug Resistance and Containment, Vector
Control, and Surveillance, Monitoring and Evaluation),
MPAC approved the convening of ERGs on diagnosis in
low transmission settings [60] and G6PD testing [61],
both of which will report back at its next meeting in
March 2014. MPAC also suggested the convening of an
ERG on Plasmodium knowlesi, which will report back to
MPAC at a future meeting.
Feedback from the MPAC meeting will also be given to
and received from the global malaria community at the
RBM Board meeting in November 2013, through the pub-
lication of this article, and subsequent correspondence.
Ongoing engagement with and attendance by inter-
ested stakeholders at MPAC meetings continues to be
encouraged. In addition to open registration for MPAC
meetings, which will continue (via the WHO-GMP web-
site starting in January 2014) and attendance by four
standing observers (RBM, the Global Fund, UNICEF,
Office of the UN Special Envoy for malaria), the active
participation of seven rotating NMCP representatives
and all six WHO Regional Malaria Advisors was strongly
welcomed.
Conclusion
The meeting feedback received from participants and ob-
servers [62], and MPAC members themselves, was very
positive. Having met four times to date, the format of
MPAC meetings and its feedback loops with other advis-
ory bodies and stakeholders is fairly settled, although it re-
mains an evolving process. WHO-GMP and the MPAC
continue to welcome strongly any feedback, support and
suggestions for improvement to MPAC meetings from the
global malaria community.
The next meeting of the MPAC will take place from
12 to 14 March, 2014 in Geneva, Switzerland. Further
information including the agenda and details on how to
register will be made available in January 2014 on the
MPAC page of the WHO-GMP website, although ques-
tions are welcome at any time [6].
Endnotes
aThe complete set of all MPAC September 2013 meeting-
related documents including background papers, presenta-
tions, and member declarations of interest can be found
online at http://www.who.int/malaria/mpac/sep2013/
en/index.html.
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